Zona Enrica, Zacchia Miriam, Di Iorio Valentina, Capolongo Giovanna, Rinaldi Luca, Capasso Giovambattista
UOC di Nefrologia e Dialisi, Università della Campania Luigi Vanvitelli, Napoli, Italia.
UOC Oftalmologia, Università della Campania Luigi Vanvitelli, Napoli, Italia.
G Ital Nefrol. 2017 Sep 28;34(5):62-72.
Bardet-Biedl Syndrome (BBS) is a rare autosomal recessive disorder with renal and extra-renal involvement. The wide spectrum of clinical manifestations is associated to the high genetic heterogeneity. To date 21 genes have been identified in humans and the majority of them encode proteins located on the basal body of the primary cilium. For this reason the disease is has been included among the 'ciliopathies'. The renal involvement is extremely heterogeneous in BBS and is considered the main cause of morbidity and mortality. Recent evidences have suggested that mutations in BBS6, 10 and 12 are associated with a more severe renal dysfunction. The most common renal dysfunction is the urine concentrating defect, even though the underlying mechanism is not completely known. Recently we have demonstrated that hyposthenuria in BBS patients has a renal origin, and depends on desmopessin resistance. The majority of hyposthenuric BBS patients have a combined defect to both concentrate and dilute the urine. The combined defect is associated with a blunted increased urine Aquaproine-2 (u-AQP2) excretion in antidiuresis. A ccordingly, in vitro BBS10 silencing prevented AQP2 trafficking to the apical plasma membrane. However, after long term water restriction hyposthenuric BBS patients showed the same u-AQP2 excretion compared with controls, suggesting that other mechanisms are implicated into the pathogenesis of hyposhtenuria. The complete molecular mechanism underlying hyposhtenuria remains largely unknown in BBS. Whether this defect may represent a predictor factor for poor renal outcome remains to be elucidated.
巴德-比德尔综合征(BBS)是一种罕见的常染色体隐性疾病,累及肾脏及肾外器官。其广泛的临床表现与高度的基因异质性相关。迄今为止,人类已鉴定出21个相关基因,其中大多数编码位于初级纤毛基体上的蛋白质。因此,该疾病被归入“纤毛病”。BBS患者的肾脏受累情况极为多样,被认为是发病和死亡的主要原因。最近有证据表明,BBS6、10和12基因的突变与更严重的肾功能障碍有关。最常见的肾功能障碍是尿液浓缩缺陷,尽管其潜在机制尚不完全清楚。最近我们证明,BBS患者的低渗尿源于肾脏,且依赖于去氨加压素抵抗。大多数低渗性BBS患者在尿液浓缩和稀释方面都存在联合缺陷。这种联合缺陷与抗利尿时尿液水通道蛋白-2(u-AQP2)排泄增加减弱有关。相应地,体外沉默BBS10可阻止AQP2转运至顶端质膜。然而,长期限水后,低渗性BBS患者的u-AQP2排泄与对照组相同,这表明低渗尿的发病机制还涉及其他机制。BBS中低渗尿的完整分子机制在很大程度上仍不清楚。这种缺陷是否可能是肾脏预后不良的预测因素仍有待阐明。